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A BS T R AC T
BACKGROUND
From the National Surgical Adjuvant
Breast and Bowel Project (NSABP)
(H.D.B., G.T., P.R., C.E.G., A.R., J.N.A.,
L.B.-D., A.M.B., R.S.M., L.F., J.A.Y., F.M.S.,
R.G., R.G.M., P.T.A., H.M.G., J.P.C., S.M.S.,
E.P.M., N.W.); the NSABP Biostatistical
Center and the Department of Biostatistics, University of Pittsburgh Graduate
School of Public Health (G.T., J.P.C.); University of Pittsburgh Cancer Institute,
University of Pittsburgh (P.R., A.M.B.);
and Allegheny General Hospital (N.W.)
— all in Pittsburgh; Medical College of
Virginia School of Medicine and the
Massey Cancer Center, Virginia Commonwealth University, Richmond (H.D.B.);
University of Texas Southwestern Medical
Center, Dallas (C.E.G.); Centre Hospitalier
de l’Université de Montréal (A.R.) and
Jewish General Hospital, McGill University (R.G.M.) — both in Montreal; South
East Cancer Control Consortium Community Clinical Oncology Program (CCOP),
Goldsboro, NC (J.N.A.); Minority-Based
CCOP, San Juan, Puerto Rico (L.B.-D.);
University of California at Irvine, Orange
(R.S.M.); Kaiser Permanente Oncology
Clinical Trials, Northern California, Vallejo,
CA (L.F.); Colorado Cancer Research Program, Colorado Springs (J.A.Y.); Northwest Medical Specialties, Tacoma, WA
(F.M.S.); CCOP, Kansas City, MO (R.G.);
Genesys Regional Medical Center, Grand
Blanc, MI (P.T.A.); CCOP, Dayton
(H.M.G.), and Aultman Hospital Cancer
Center, Canton (E.P.M.) — both in Ohio;
and Washington Cancer Institute, Medstar
Washington Hospital Center, Washington,
DC (S.M.S.). Address reprint requests to
Dr. Bear at Box 980011, Division of Surgical Oncology, VCUHS, Richmond, VA
23298-0011, or at hdbear@vcu.edu.
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Bevacizumab and the antimetabolites capecitabine and gemcitabine have been shown
to improve outcomes when added to taxanes in patients with metastatic breast
cancer. The primary aims of this trial were to determine whether the addition of
capecitabine or gemcitabine to neoadjuvant chemotherapy with docetaxel, followed by
doxorubicin plus cyclophosphamide, would increase the rates of pathological complete
response in the breast in women with operable, human epidermal growth factor receptor 2 (HER2)–negative breast cancer and whether adding bevacizumab to these
chemotherapy regimens would increase the rates of pathological complete response.
METHODS

We randomly assigned 1206 patients to receive neoadjuvant therapy consisting
of docetaxel (100 mg per square meter of body-surface area on day 1), docetaxel
(75 mg per square meter on day 1) plus capecitabine (825 mg per square meter
twice a day on days 1 to 14), or docetaxel (75 mg per square meter on day 1) plus
gemcitabine (1000 mg per square meter on days 1 and 8) for four cycles, with all
regimens followed by treatment with doxorubicin–cyclophosphamide for four cycles.
Patients were also randomly assigned to receive or not to receive bevacizumab (15 mg
per kilogram of body weight) for the first six cycles of chemotherapy.
RESULTS

The addition of capecitabine or gemcitabine to docetaxel therapy, as compared with
docetaxel therapy alone, did not significantly increase the rate of pathological complete response (29.7% and 31.8%, respectively, vs. 32.7%; P = 0.69). Both capecitabine and gemcitabine were associated with increased toxic effects — specifically, the
hand–foot syndrome, mucositis, and neutropenia. The addition of bevacizumab significantly increased the rate of pathological complete response (28.2% without bevacizumab vs. 34.5% with bevacizumab, P = 0.02). The effect of bevacizumab on the rate
of pathological complete response was not the same in the hormone-receptor–positive and hormone-receptor–negative subgroups. The addition of bevacizumab increased the rates of hypertension, left ventricular systolic dysfunction, the hand–foot
syndrome, and mucositis.
CONCLUSIONS

The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the
rate of pathological complete response, which was the primary end point of this study.
(Funded by the National Cancer Institute and others; ClinicalTrials.gov number,
NCT00408408.)
n engl j med 366;4
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eoadjuvant chemotherapy has become established as a reasonable alternative to adjuvant chemotherapy for operable
breast cancer, since it can increase the rates of
breast-conserving surgery1-3 and decrease the need
for complete axillary lymph-node dissection.4-6
Neoadjuvant chemotherapy also offers the potential
for rapidly testing regimens that may improve response rates and therefore may be likely to improve
the outcomes in patients. Although alterations in
neoadjuvant chemotherapy that increase the rates
of pathological complete response may not necessarily improve survival,5,7 the results of the National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-27 trial (ClinicalTrials.gov number,
NCT00002707) of neoadjuvant therapy were concordant with those of randomized trials of adjuvant
therapy that showed improved outcomes with the
addition of taxanes.3,8-11 Evaluation of responses of
tumors to neoadjuvant therapy in patients who have
not previously been exposed to systemic therapies
could be a more useful strategy for determining the
drugs or regimens that are worth testing in trials
of adjuvant therapy than a strategy of using results
from studies involving patients with metastatic disease. Furthermore, the neoadjuvant setting allows
for the collection of tissues that can be used to
identify predictors of treatment response and that
can inform the design of future trials of adjuvant
therapy.
Bevacizumab (Avastin, Genentech), an antiangiogenic monoclonal antibody against vascular
endothelial growth factor (VEGF) A, and the antimetabolites capecitabine and gemcitabine have
been shown to improve the outcomes when added
to taxanes in patients with metastatic breast cancer. Bevacizumab added to chemotherapy increased
progression-free survival and the rates of response,
but not overall survival, in prospective, randomized
trials involving patients with metastatic breast
cancer.12-14 The addition of capecitabine to the
taxane docetaxel in patients with locally advanced
or metastatic disease increased the rates of objective response and significantly prolonged the
median time to progression and the median overall survival.15 In a phase 3, randomized trial, gemcitabine added to paclitaxel significantly increased
the rates of response, the median time to progression, and the median overall survival.16 With that
background, we sought to determine whether adding capecitabine or gemcitabine to docetaxel, followed by the anthracycline doxorubicin plus cyclophosphamide, would improve the outcomes in
n engl j med 366;4

patients with operable, human epidermal growth
factor receptor 2 (HER2)–negative breast cancer
and to determine the effect of the addition of
bevacizumab to these neoadjuvant chemotherapy
regimens.

Me thods
Patient Eligibility and Entry Procedures

Women with primary operable HER2-negative
breast cancer diagnosed by means of a core needle
biopsy were eligible for participation in the study.
Patients were required to have a palpable primary
tumor at least 2.0 cm in diameter in the breast, as
assessed by physical examination, and to be classified as having tumor stage T1c to T3, nodal stage
N0 to N2a, and metastasis stage M0. Other key eligibility criteria were an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
1 (with 0 indicating that the patient is fully active
and able to carry on all predisease activities without restriction and 1 indicating that the patient is
restricted in physically strenuous activity but is ambulatory and able to carry out work of a light or
sedentary nature, such as light housework or office work) and normal left ventricular ejection fraction, determined by multiple-gated acquisition
scanning or echocardiography within 3 months
before study entry. Before random assignment, patients were required to have core-biopsy material
harvested for correlative science studies.
The assignment to treatment groups was balanced according to age at entry (≤49 or ≥50 years),
clinical tumor size (2.0 to 4 cm or ≥4.1 cm), hormone-receptor status (estrogen-receptor–positive,
progesterone-receptor–positive, or both vs. estrogenreceptor–negative and progesterone-receptor–negative), and clinical nodal status (negative vs. positive). Randomization was performed within these
strata, with the use of a biased-coin approach to
ensure balanced treatment assignments within an
institution.
Study Oversight

The protocol was approved by the central institutional review board of the National Cancer Institute
(NCI) and by the human investigations committee
or institutional review board at each participating
site, each of which has approval for human subjects research from the Department of Health
and Human Services. Written informed consent
was obtained from all participants. The first
author wrote the first draft of the manuscript,
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and all the authors contributed to subsequent
drafts and made the decision to submit the manuscript for publication. A group of NSABP authors ensured the fidelity of the study to the protocol. F. Hoffmann–La Roche, Genentech USA,
and Eli Lilly provided partial support for this
trial and were provided an opportunity to review
the manuscript before submission for publication.
The NSABP restricts the access of sponsors to outcomes data until the time of publication. The study
had no additional commercial support, and no
person other than the authors contributed to the
content of the manuscript. The protocol, including the statistical analysis plan, is available with
the full text of this article at NEJM.org.
Treatment

Eligible patients were randomly assigned to one
of three neoadjuvant chemotherapy regimens:
four cycles of docetaxel (100 mg per square meter
of body-surface area, administered intravenously
on day 1 of the cycle) every 3 weeks, followed by
four cycles of doxorubicin–cyclophosphamide
(60 mg and 600 mg per square meter, respectively, administered intravenously every 3 weeks)
(docetaxel group); capecitabine (825 mg per square
meter, administered orally twice a day on days
1 through 14) added to docetaxel (75 mg per
square meter, administered intravenously on day
1), followed by doxorubicin–cyclophosphamide
(docetaxel–capecitabine group); or gemcitabine
(1000 mg per square meter, administered intravenously on days 1 and 8) added to docetaxel (75 mg
per square meter, administered intravenously on
day 1), followed by doxorubicin–cyclophosphamide (docetaxel–gemcitabine group) (see Fig. S1
in the Supplementary Appendix, available at
NEJM.org). Half the patients were also randomly
assigned to receive bevacizumab (15 mg per kilogram of body weight, administered intravenously,
every 3 weeks) with each of the first six cycles of
chemotherapy and for 10 additional doses every
3 weeks postoperatively (Fig. S1 in the Supplementary Appendix). Bevacizumab was stopped after
cycle 6 for a washout before surgery in order to
reduce the risk of surgical complications.
Patients who were considered to be candidates
for breast-conserving surgery were to have the
primary tumor site marked (with clips or tattoos)
before the initiation of chemotherapy. Patients
underwent surgery after they had recovered from
chemotherapy, the final tumor assessments had
312
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been performed, and cardiac function had been
evaluated. For patients receiving bevacizumab
who underwent all four cycles of doxorubicin–
cyclophosphamide, surgery was performed at least
9 weeks after the last dose of bevacizumab. If
chemotherapy was stopped before completion of
the planned therapy, surgery was performed at
least 4 weeks, and preferably 6 weeks, after the
last dose of bevacizumab. The type of surgery that
was performed was left to the discretion of the
patient and surgeon. For patients undergoing
breast reconstruction, tissue expansion could not
be performed within the 2 weeks before the first
postoperative dose of bevacizumab. Expansion or
any surgical procedure (e.g., exchanging tissue expanders for permanent implants) was prohibited
throughout the course of bevacizumab therapy and
a minimum period of 6 weeks after the last dose
of bevacizumab. Post-lumpectomy breast radiation
therapy was required after breast-conserving surgery. Partial breast irradiation was not permitted.
Decisions regarding regional-node irradiation and
post-mastectomy irradiation were made at the discretion of the patient’s physician. Patients with
estrogen-receptor–positive or progesterone-receptor–positive tumors received endocrine therapy for
a minimum of 5 years after the completion of
neoadjuvant chemotherapy and surgery. The selection of endocrine agents was left to the discretion
of the physicians.
End Points

The primary end point was the rate of pathological
complete response in the breast. Secondary end
points included the rate of pathological complete
response in the breast and nodes; clinical complete
responses after the docetaxel-based portion of the
chemotherapy program had been completed; clinical complete responses after completion of the
entire sequential chemotherapy program; the percentage of patients with cardiac events, defined
as New York Heart Association (NYHA) class III
or IV congestive heart failure; and toxic effects,
including cardiac events other than congestive
heart failure.
Assessments of Tumor Response and Adverse
Events

The assessment of tumor response was based on
modifications of the criteria proposed by the Response Evaluation Criteria in Solid Tumors Group.17
A pathological complete response in the breast
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was defined as the absence of histologic evidence
of invasive tumor cells in the surgical breast specimen. A pathological complete response in the
breast and nodes was defined as the absence of
histologic evidence of invasive tumor cells in the
surgical breast specimen, axillary nodes, and
nonaxillary sentinel nodes identified after neoadjuvant chemotherapy. Disease progression was
defined as the unequivocal progression of existing
target or nontarget lesions; the appearance of one
or more new lesions in the breast, regional lymph
nodes, or distant sites; or the appearance of inflammatory carcinoma on clinical examination. Adverse
events were graded according to the NCI Common
Terminology Criteria for Adverse Events, version
3.0 (http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/docs/ctcaev3.pdf).
Statistical Analysis

There were two primary hypotheses: that the addition of capecitabine or gemcitabine would improve the rate of pathological complete response in
the breast, and that the addition of bevacizumab
would improve the rate of pathological complete
response in the breast. The estimation of the sample size was based on the comparison among chemotherapy regimens. Assuming that the rate of
pathological complete response in the docetaxel
group would be 26%, we estimated that we would
need to enroll 400 patients in each of the three
docetaxel-based groups for the study to have 80%
power to detect a significantly different rate of
36% for pathological complete response in either
the capecitabine group or the gemcitabine group,
with a type I error rate of 0.05.
The analyses of end-point data are based on
information gathered as of June 30, 2011. The
maximum of two standardized pairwise differences in the rates of pathological complete response between the docetaxel group and the other
two groups, with or without bevacizumab, was
used for testing the improvement in the outcome
with the addition of capecitabine or gemcitabine.18
The critical value for a 0.05 significance level is
2.21, which was calculated from 10,000 simulations with adjustment for multiple comparisons.18
The Pearson chi-square test with continuity adjustment19 was used to assess the association
between treatment and response variables. The
Breslow–Day test was performed to assess the homogeneity of the odds ratios across randomization
strata and histologic grades.19 If there was no evin engl j med 366;4

dence against the homogeneity of odds ratios, the
Mantel–Haenszel estimate of the common odds
ratio was calculated in addition to the gross odds
ratio.20 All statistical analyses were performed
with the use of SAS software, version 9.2, and
the R statistical package, version 2.11.

R e sult s
Characteristics of the Patients
and the Tumors

Between January 5, 2007, and June 30, 2010, a total
of 1206 patients were enrolled (Fig. S1 in the Supplementary Appendix). The characteristics of the
patients and the tumors were well balanced across
the treatment groups (Table 1, and Table S1 in the
Supplementary Appendix). A total of 47% of the patients had clinically positive nodes, 55% of the tumors were poorly differentiated, and 59% of the
tumors were hormone-receptor–positive. The hormone-receptor status was assessed at the participating institutions according to their own criteria
for positivity.
The primary analyses were performed on data
from all patients who underwent randomization
and for whom outcomes were ascertained. Assessments of the primary end point, pathological complete response in the breast, were available for
1186 of the 1206 patients who underwent randomization; among the 20 patients who were not included in the primary analyses, 13 withdrew consent and 7 had missing data. Two of the 1186
patients had inoperable disease after chemotherapy.
An additional 20 patients (1.7%), with a balanced distribution across the treatment groups,
were found after randomization to be ineligible:
6 did not have preentry measurements of the urinary protein:creatinine ratio, 3 had stage T4 tumors, 2 had HER2-positive cancer, and 9 had
various other reasons. The secondary analyses, including subgroup analyses, were performed on
data from the 1166 eligible patients.
Effects of Adding Capecitabine
or Gemcitabine

The addition of capecitabine or gemcitabine did not
increase the rate of pathological complete response
in the breast (P = 0.26, with adjustment for multiple comparisons according to the Dunnett method). There were no significant differences among
the three chemotherapy regimens with respect to
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Table 1. Baseline Characteristics of the Patients and the Tumors.*
Docetaxel plus
Docetaxel Bevacizumab

Characteristic
Total cohort (no.)
Ineligible patients (no.)

Docetaxel–
Docetaxel–
Docetaxel– Capecitabine plus Docetaxel– Gemcitabine plus
Capecitabine
Bevacizumab
Gemcitabine
Bevacizumab
P Value

201

199

204

201

197

204

1

4

4

4

5

2

54

52

50

53

52

52

Age at entry (%)

0.98

≤49 yr
50–59 yr

31

33

32

28

34

31

≥60 yr

14

15

18

19

14

17

2–4 cm

44

43

48

47

45

46

>4 cm

56

57

52

53

55

54

Positive

48

47

46

46

46

46

Negative

52

54

54

54

54

54

Clinical tumor size (%)

0.98

Clinical nodal status (%)

1.00

Hormone-receptor status (%)

1.00

Positive

60

60

58

59

59

60

Negative

40

40

42

41

41

40

White

84

87

80

87

76

86

Black

12

10

17

10

17

14

Other

3

3

3

3

7

<1

7

6

7

8

8

6

Intermediate

36

35

33

38

33

38

High

55

57

58

53

56

53

1

2

2

<1

3

2

Race (%)†

0.06

Histologic grade of tumor (%)
Low

Unknown

0.88

0.99

* Patients were randomly assigned to receive docetaxel, docetaxel–capecitabine, or docetaxel–gemcitabine for four cycles, followed in all
groups by four cycles of doxorubicin–cyclophosphamide. In addition, half the patients were also randomly assigned to receive bevacizumab
with each of the first six cycles of chemotherapy.
† Race was self-reported.

the rate of pathological complete response in the
breast or the rate of pathological complete response
in the breast and nodes (rates of pathological complete response in the breast, 32.7% with docetaxel,
29.7% with docetaxel–capecitabine, and 31.8%
with docetaxel–gemcitabine; P = 0.69 with the use
of Pearson’s chi-square test with continuity adjustment; rates of pathological complete response in
the breast and nodes, 25.8%, 23.2%, and 26.9%,
in the three groups, respectively; P = 0.51) (Fig. 1).
The results for the 1166 eligible patients were similar (P = 0.76 and P = 0.53 for the comparisons of
pathological complete response in the breast and
in the breast and nodes, respectively). Subset anal314

n engl j med 366;4

yses according to clinical tumor size, clinical nodal status, hormone-receptor status, age, and tumor
grade did not show significant differences among
the chemotherapy regimens in any subgroup of
patients (Fig. S2 in the Supplementary Appendix).
Clinical responses were assessed after completion of the docetaxel-based cycles in the case of
1155 patients and before surgery in the case of
1163. The rates of clinical complete response in the
three chemotherapy groups were similar after the
four docetaxel-based cycles (36.6% with docetaxel,
32.3% with docetaxel–capecitabine, and 40.2%
with docetaxel–gemcitabine; P = 0.09) and after
completion of all chemotherapy before surgery
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A Breast
40
35

B Breast and Nodes
P=0.69 by chi-square test
32.7
29.7

31.8

35
30

Percent pCR

Percent pCR

30
25
20
15

5
0

TG–AC
(N=393)

C Breast
40

40

28.2

TG–AC
(N=390)

P=0.08 by chi-square test

27.6

30

25
20
15

20
15
10

5

5

Without Bevacizumab
(N=595)

0

Bevacizumab
(N=591)

23.0

25

10

0

TX–AC
(N=393)

35

Percent pCR

30

T–AC
(N=392)

D Breast and Nodes
P=0.02 by chi-square test
34.5

35

Percent pCR

15
10

TX–AC
(N=398)

23.2

20

5

T–AC
(N=395)

26.9

25.8

25

10

0

P=0.51 by chi-square test

40

Without Bevacizumab
(N=591)

Bevacizumab
(N=584)

Figure 1. Pathological Complete Response (pCR).
The percentages of patients with pCR in the breast (Panel A) and in the breast and nodes (Panel B) are shown according to chemotherapy regimen (docetaxel followed by doxorubicin–cyclophosphamide [T–AC], docetaxel and
capecitabine followed by doxorubicin–cyclophosphamide [TX–AC], or docetaxel and gemcitabine followed by doxorubicin–cyclophosphamide [TG–AC]). In addition, the percentages of patients with pCR in the breast (Panel C) and
in the breast and nodes (Panel D) are shown according to receipt or no receipt of bevacizumab.

(58.3%, 55.4%, and 56%, respectively; P = 0.74). The
rates of clinical partial response were also similar
(Table S2 in the Supplementary Appendix). The
proportions of patients who underwent breastconserving surgery were similar in the three
groups (46%, 43%, and 50%, respectively).
Effects of Adding Bevacizumab

The addition of bevacizumab significantly increased the rate of pathological complete response
in the breast, from 28.2% to 34.5% (P = 0.02) (Fig.
1C). When the rate of pathological complete response was examined according to hormone-receptor status, the effect of bevacizumab was more
pronounced in the hormone-receptor–positive
subset (15.1% without bevacizumab vs. 23.2% with

n engl j med 366;4

bevacizumab, P = 0.007), with a weaker effect in the
hormone-receptor–negative subset (47.1% without
bevacizumab vs. 51.5% with bevacizumab, P = 0.34).
The effects of adding bevacizumab on the rates of
pathological complete response in the 1166 eligible patients were similar to those in the primaryanalysis cohort (P = 0.02 for the effect in the overall
cohort, P = 0.005 for the effect in the hormonereceptor–positive subset, and P = 0.29 for the effect
in the hormone-receptor–negative subset). However, the Breslow–Day test for homogeneity of odds
ratios across hormone-receptor subsets was not
significant (P = 0.19) (Fig. 2A). The rate of pathological complete response in the breast was significantly increased when bevacizumab was added to
the docetaxel–capecitabine regimen (36.1% vs.
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A Breasts
P Value for
Breslow–
Day Test

Subgroup
All patients
Clinical tumor size
2–4 cm
>4 cm
Clinical nodal status
Positive
Negative
Hormone-receptor status
Positive
Negative
Age at entry
<50 yr
≥50 yr
Tumor grade
Low
Intermediate
High

0.68

0.11

0.19

0.73

0.57

0.25

0.50

1.00

pCR Lower

2.00

4.00

pCR Higher

B Breasts and Nodes
P Value for
Breslow–
Day Test

Subgroup
All patients
Clinical tumor size
2–4 cm
>4 cm
Clinical nodal status
Positive
Negative
Hormone-receptor status
Positive
Negative
Age at entry
<50 yr
≥50 yr
Tumor grade
Low
Intermediate
High

0.76

0.44

0.24

0.94

0.73

0.25

0.50

pCR Lower

1.00

2.00

4.00

pCR Higher

Figure 2. Subgroup Analyses of the Effect of Bevacizumab on Pathological
Complete Response (pCR).
The effect of bevacizumab with respect to pCR in the breast (Panel A) and
in the breast and nodes (Panel B) is shown across various subgroups of
eligible patients. P values were calculated from tests for the homogeneity
of the effects of bevacizumab across patient subgroups.

316

n engl j med 366;4

of

m e dic i n e

23.5%, P = 0.009) but not when it was added to the
docetaxel–gemcitabine regimen (35.8% vs. 27.6%,
P = 0.10) or the docetaxel regimen (31.6% vs. 33.7%,
P = 0.75). The P value for the test for homogeneity of the odds ratios according to chemotherapy
regimen was 0.07. The results from the multiple
logistic-regression model showed that hormonereceptor–negative status, high tumor grade, and
smaller tumor size were associated with higher
rates of pathological complete response in the
breast (Table S3 in the Supplementary Appendix).
There was an increase in the rate of pathological complete response in the breast and nodes with
bevacizumab therapy, but the difference in the
overall cohort was not significant (23.0% without
bevacizumab vs. 27.6% with bevacizumab, P = 0.08)
(Fig. 1D); however, in the hormone-receptor–positive subset, the increase with the addition of bevacizumab therapy did reach significance (11.1%
without bevacizumab vs. 16.8% with bevacizumab,
P = 0.03). Again, however, the test for homogeneity
of the odds ratios was not significant (P = 0.25).
The results in eligible patients were similar to
those in the primary-analysis cohort (Fig. 2B).
There was also a trend toward a greater effect of
bevacizumab with an increase in tumor grade, but
the test for homogeneity of the odds ratios was not
significant (Fig. 2B).
The addition of bevacizumab increased the
rate of clinical complete response, with a rate of
51.7% among patients who did not receive bevacizumab, as compared with 61.5% among those
who received bevacizumab (P<0.001). All classes
of clinical responses, in patients who received
bevacizumab and in patients who did not receive
bevacizumab, are shown in Table S4 in the Supplementary Appendix. The effect of bevacizumab
on clinical complete response was similar to the
effect on pathological complete response, with a
more pronounced effect in the hormone-receptor–
positive subset (50.7% without bevacizumab vs.
62.2% with bevacizumab, P = 0.003) than in the
hormone-receptor–negative subset (53.1 without
bevacizumab vs. 60.4% with bevacizumab, P = 0.14).
Toxic Effects

Table S5 in the Supplementary Appendix shows
the percentages of patients who completed all
planned neoadjuvant treatments and the reasons
for discontinuation for those who did not. A total
of 83% of the patients who did not receive beva-
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Table 2. Rates of Toxic Effects in the Three Chemotherapy Groups.*
Docetaxel
(N = 396)

Toxic Effect
Grade 2

Grade 3

Docetaxel–Capecitabine
(N = 399)
Grade 4

Grade 2

Grade 3

Grade 4

Docetaxel–Gemcitabine
(N = 396)
Grade 2

Grade 3

Grade 4

P Value

percent of patients
16

48

7

20

56

13

14

61

11

Leukopenia

Overall†

0

5

<1

0

4

1

0

9

1

<0.001
0.17

Neutropenia

0

10

5

0

13

7

0

26

8

<0.001

Hypertension

7

6

<1

7

5

<1

9

5

0

0.94

Left ventricular systolic
dysfunction

2

0

0

<1

2

0

1

<1

<1

0.43

Fatigue

0

9

0

0

10

<1

0

9

0

0.97
<0.001

9

3

0

28

23

0

3

1

0

Rash

Hand–foot syndrome

11

<1

<1

9

1

<1

17

<1

0

0.03

Diarrhea

10

3

0

16

8

<1

14

7

0

0.02

Mucositis

8

2

0

16

4

<1

13

3

0

0.01

Nausea

0

3

0

0

5

0

0

5

<1

0.91

Vomiting

0

2

0

0

4

0

0

6

<1

0.46

Febrile neutropenia

0

6

0

0

10

<1

0

8

<1

0.61

Infection in wound

0

1

0

0

1

0

0

2

0

0.83

Sensory neuropathy

13

4

0

13

4

0

8

2

0

0.04

Bone pain

0

6

<1

0

2

0

0

3

0

0.12

Headache

0

2

<1

0

2

<1

0

3

0

0.95

Dyspnea
Thrombosis, thrombus,
or embolism

5

<1

0

2

2

<1

5

1

<1

0.40

<1

<1

<1

1

2

2

1

2

<1

0.73

* Patients in all three groups were randomly assigned to receive four cycles of the assigned therapy, followed by four cycles of doxorubicin–
cyclophosphamide.
† The rate of death in the overall cohort during the treatment period was less than 1% in the docetaxel and docetaxel–capecitabine groups
and 0 in the docetaxel–gemcitabine group.

cizumab, as compared with 78% of those who received bevacizumab, completed all planned preoperative therapy. Tables 2 and 3 list the overall
incidences of toxic effects, toxic effects (grades
2, 3, or 4) occurring in more than 5% of the patients, treatment-related deaths, and other serious
toxic effects in the three chemotherapy groups
(Table 2) and in all patients according to whether
they received or did not receive bevacizumab (Table 3). The addition of capecitabine or gemcitabine
increased the rate of overall toxic effects. In the
docetaxel–capecitabine group, the increased rate of
toxic effects was largely the result of increases in
grades 2 and 3 hand–foot syndrome. In the doce
taxel–gemcitabine group, the toxic effect with
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the greatest increase in frequency, as compared
with the toxic effects seen with docetaxel alone,
was neutropenia.
The addition of bevacizumab to chemotherapy
also increased the toxic effects, particularly the
rates of hypertension, mucositis, and the hand–
foot syndrome (Table 3). The patients who received
bevacizumab also had a significant increase in
left ventricular dysfunction. A total of 8 patients
(1.3%) who received bevacizumab, as compared
with 1 patient (0.2%) who did not receive bevaciz
umab, had left ventricular dysfunction of grade
3 or grade 4 (with the one case of grade 4 left
ventricular dysfunction in the bevacizumab group);
the majority of cases were grade 2 (11 in the group
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Table 3. Rates of Toxic Effects, According to Receipt or No Receipt of Bevacizumab.*
Toxic Effect

No Bevacizumab (N = 596)
Grade 2

Grade 3

Grade 4

Bevacizumab (N = 595)
Grade 2

Grade 3

P Value

Grade 4

percent of patients
18

49

9

15

61

12

<0.001

Leukopenia

Overall†

0

6

1

0

6

<1

0.47

Neutropenia

0

16

6

0

16

7

1.00

Hypertension

1

<1

0

13

10

<1

<0.001

<1

<1

0

2

1

<1

0.02

0

9

<1

0

10

<1

0.95

Left ventricular systolic dysfunction
Fatigue
Hand–foot syndrome

11

7

0

15

11

0

0.008

Rash

10

<1

<1

14

1

<1

0.34

Diarrhea

13

7

<1

14

5

0

0.67

Mucositis

11

1

0

14

4

<1

0.007

Nausea

0

4

<1

0

5

0

0.99

Vomiting

0

5

<1

0

3

0

0.45

Febrile neutropenia

0

6

<1

0

10

<1

0.15

Infection in wound

0

<1

0

0

3

0

1.00

Sensory neuropathy

11

3

0

12

4

0

0.55

Bone pain

0

3

<1

0

4

0

0.39

Headache

0

<1

0

0

4

<1

0.01

4

<1

0

4

1

<1

0.69

<1

1

<1

1

2

1

0.78

Dyspnea
Thrombosis, thrombus, or embolism

* Patients were randomly assigned to receive bevacizumab with each of the first six cycles of chemotherapy.
† The rate of death in the overall cohort during the treatment period was less than 1% in both groups.

that received bevacizumab vs. 1 in the group that
did not receive bevacizumab) (Table 3). A more
detailed analysis of the effect on left ventricular
function of adding bevacizumab is provided in
Table S6 in the Supplementary Appendix. There
was a low incidence of wound complications in
the group that received bevacizumab, but the rate
was significantly higher than the rate in the group
that did not receive bevacizumab (2% vs. 0%,
P = 0.002).

Discussion
In this trial, neither capecitabine nor gemcitabine
added to an anthracycline–taxane based chemotherapy regimen improved the rates of clinical or
pathological response, despite the suggestive results that have been seen in patients with metastatic breast cancer. Thus, it appears unlikely that
these drugs would add much benefit in the adjuvant
318
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setting. Indeed, our results confirm (and would
have predicted) the largely negative results of several trials of adjuvant therapy with these drugs,21-23
supporting our hypothesis that trials of neoadjuvant therapy serve as better predictors of adjuvant
benefits than studies of metastatic disease. The
addition of bevacizumab resulted in a modest but
significant increase in the rate of pathological complete response in the breast, but the rate of pathological complete response in the breast and
nodes was not significantly increased, which may
indicate that this drug will have a lesser effect on
patient outcomes. Moreover, adding bevacizumab
increased a number of toxic effects. Left ventricular dysfunction was noted as a serious concern in
a recent meta-analysis of bevacizumab therapy in
patients with metastatic breast cancer.24 Left ventricular function and wound complications are being closely monitored in patients receiving adjuvant
bevacizumab therapy as well as in the long-term
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follow-up of these patients. It is unclear why the
greatest benefit from adding an antiangiogenic
agent was seen in patients with hormone-receptor–
positive tumors, in contrast to the findings in the
GeparQuinto trial (NCT00567554), reported by
von Minckwitz et al. elsewhere in this issue of
the Journal,25 in which the benefit was confined to
patients with hormone-receptor–negative tumors.
The disparity in the results of the two trials may
be related to differences in the inclusion criteria
and the study design, particularly the inclusion in
the GeparQuinto trial of patients with more advanced disease, a different sequencing of drug
regimens in the GeparQuinto trial than that in our
trial, and the withdrawal from the GeparQuinto
study of patients who did not have a response to
the initial four cycles of treatment.25
The benefit of bevacizumab in our study also
tended to be seen in patients with a high tumor
grade (Fig. 2A and 2B), a finding that was also
observed in the GeparQuinto study. The increased
rate of pathological complete response in patients
with hormone-receptor–positive tumors is encouraging, since this group tends to have low rates of
pathological complete response with chemotherapy. The addition of an antimetabolite (capecitabine
or gemcitabine) in two thirds of our patients, with
a concomitant decrease in the dose of docetaxel,
might account for the disproportionate effect of
adding bevacizumab in the docetaxel–capecitabine
and docetaxel–gemcitabine groups. The effect of

adding bevacizumab in the NSABP B-40 trial was
less dramatic than was the effect of adding
docetaxel in the NSABP B-27 trial, so it is not clear
whether the neoadjuvant effect of bevacizumab
would translate into a substantial benefit to patients. However, the groups that were randomly
assigned to bevacizumab in our trial also received
bevacizumab postoperatively, so the potential for
bevacizumab to improve the outcomes should be
clarified when the results with respect to diseasefree survival and overall survival are available from
the NSABP B-40 trial and from studies of adjuvant
bevacizumab therapy that are currently in progress. In addition, the collection of tissue samples
from all our patients before treatment, a major
advantage of the neoadjuvant approach, offers an
opportunity to discover molecular markers that
might predict a benefit from bevacizumab. Such
markers would allow the selective use of this agent
in the subsets of patients most likely to have improved outcomes with the use of the drug.
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